

### SUPPORT FOR THE AMENDMENTS

Support for the amendments to Claims 1, 11-13, and 15 can be found in Claims 2 and 7, at column 8, lines 53-55, and column 9, lines 10-14.

No new matter is believed to be introduced by the above amendment.


### REMARKS

Claims 1, 11-13, and 15 have been amended to delete the requirement that said aspartame is present in said composition in an amount of 50 to 97% by weight based on the total amount of said aspartame and said N-[N-(3,3-dimethylbutyl)-L- $\alpha$ -aspartyl]-L-phenylalanine 1-methyl ester and to insert wherein said N-[N-(3,3-dimethylbutyl)-L- $\alpha$ -aspartyl]-L-phenylalanine 1-methyl ester comprises a C-type crystal (Claim 12) or a C-type or an A-type crystal (Claims 1, 11, 13, and 15).

Applicants submit that the present application is now in condition for allowance, and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Stephen G. Baxter, Ph.D.  
Attorney of Record  
Registration No. 32,884

Tel: (703) 413-3000  
Fax: (703) 413-2220